46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Removal of Endotoxin from Recombinant Protein Preparations

      , , , , ,
      Clinical Biochemistry
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To develop an effective method to remove endotoxin from large scale E. coli recombinant protein purifications. Triton X-114 phase separation, affinity chromatography utilizing immobilized polymyxin B or immobilized histidine, were used to remove endotoxin from purified preparations of recombinant CK-BB, CK-MB, CK-MM, myoglobin, and cardiac troponin I. Endotoxin levels were measured by a Limulus Amebocyte Lysate gel-clot assay. The immunoactivity of these protein preparations was determined by BIAcore analysis using a panel of in-house generated monoclonal antibodies and by a Stratus Fluorometric Analyzer. In the case of troponin I, the BIAcore was also utilized to measure troponin C interactions. Phase separation with Triton X-114 was the most effective method in reducing the amount of endotoxin present in the protein preparations compared to either polymyxin B or histidine affinity chromatography. With Triton X-114, the reduction in endotoxin levels was greater than 99% and recovery of the proteins after endotoxin removal was greater than 90%. All three procedures for removing endotoxin had no deleterious effects on the immunoactivity of majority proteins when tested with a panel of monoclonal antibodies. Troponin I also retained its ability to bind to troponin C in the presence of Ca2+. Recombinant CK-BB and CK-MM which were expressed in the soluble fraction of E. coli cell lysates, contained significantly higher endotoxin levels than recombinant CK-MB, myoglobin and cardiac troponin I which were expressed in the form of inclusion bodies. Of the three methods tested, Triton X-114 phase separation was the most effective way of removing endotoxin from recombinant proteins.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: not found
          • Article: not found

          Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity

            Treatment of rats with recombinant human TNF initially causes a marked decrease in food intake, a loss of body weight, and a negative nitrogen balance. These alterations normalize with continued twice daily intraperitoneal injections of the same dose. Rats tolerized to TNF in this manner are refractory to a lethal dose of TNF. Also, TNF- pretreated and -tolerized rats have prolonged survival and reversed histopathologic changes after injection of a lethal dose of endotoxin compared with control animals. The TNF-tolerant state is dependent on the dose of TNF used and the length of TNF pretreatment. TNF-induced tolerance is relatively short lived, being present 2-4 d after TNF pretreatment and dissipating by 2 wk. Rats made tolerant to endotoxin are also tolerant to a lethal dose of TNF. A bidirectional crossreacting tolerance exists between TNF and endotoxin. The mechanism of TNF tolerance is unclear, but it does not appear to be due to a humoral immune response or a perturbation of the uptake and clearance of injected TNF.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Inflammatory Effects of Endotoxin-Like Contaminants in Commonly Used Protein Preparations

                Bookmark

                Author and article information

                Journal
                Clinical Biochemistry
                Clinical Biochemistry
                Elsevier BV
                00099120
                August 1997
                August 1997
                : 30
                : 6
                : 455-463
                Article
                10.1016/S0009-9120(97)00049-0
                9316739
                df65c4c0-79a1-48ff-8777-ef67ccebca1f
                © 1997

                https://www.elsevier.com/tdm/userlicense/1.0/

                History

                Comments

                Comment on this article